Esreboxetine
Small molecule
Evidence outlook · registrational
Fibromyalgia: registrational readout pending
Its supporting mid-stage studies have completed. ClinicalTrials.gov estimates the registrational readout at 2028-03; company guidance (Axsome Therapeutics, stated 2026-11-02): topline data expected 3Q 2027.
Company guidance: topline data expected 3Q 2027 (NCT07398417; Axsome Therapeutics, 2 Nov 2026). “AXS-14 for the management of fibromyalgia Key eligibility criteria ≥18 years of age with diagnosis of fibromyalgia Primary endpoint Time from randomization to loss of therapeutic response FORWARD Phase 3 trial Placebo AXS-14 (8 mg) Open-label period (12 weeks) Double-blind phase (up to 12 weeks) Baseline 1:1 R AXS-14 (8 mg) 1:1 randomization (Patients achieving treatment response) 45 Enrollment completion anticipated 3Q 2027” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
FORWARD NCT07398417 · Fibromyalgia Registry: NCT07398417 | 3 | Time from randomization to loss of therapeutic response (12 Weeks) 2028-03 | In progress: results expected 1 Mar 2028 | not yet graded | link ↗ |
View 2 more trials
NCT07637162 NCT07637162 · Fibromyalgia Registry: NCT07637162 | 3 | Long-term Safety (Up to 52 weeks.) 2028-05 | In progress: results expected 1 May 2028 | not yet graded | link ↗ |
NCT00612170 NCT00612170 · Fibromyalgia Registry: NCT00612170 | 3 | Change from baseline in the endpoint mean pain score (14 weeks); Fibromyalgia Impact Questionnaire (14 weeks) 2009-05 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
Other norepinephrine transporter drugs
viloxazine, Reboxetine. Compare all 3 norepinephrine transporter drugs
3 other tracked programmes target this mechanism, 1 of them ahead of this one.
This drug's own stage for Fibromyalgia: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Esreboxetine: this drug | Phase 3 | Small molecule | norepinephrine transporter | not yet graded | No reviewed efficacy summary in this indication | |
| Cyclobenzaprine (Tonmya) | Approved | Small molecule | 5-HT2A, α1-adrenergic, H1-histaminergic, and M1-muscarinic acetylcholine receptors (functional antagonism) | Partial signal | NCT04172831: Change in weekly average daily pain (NRS) from baseline to week 14: TNX-102 SL 5.6 mg -1.9 vs placebo -1.5; LS mean difference -0.4 (95% CI -0.7 to -0.1), p=0.010 (n=248 and 255) (CT.gov posted results). NCT04508621: Change From Baseline to Week 14 in the Numerical Rating Scale (NRS) Weekly Average of Daily Self-reported Average Pain Severity Scores. (14 weeks): TNX-102 SL Tablet, 5.6 mg -1.6 score on a scale (95% CI -1.8 to -1.3) | Placebo SL Tablet -1.3 score on a scale (95% CI -1.5 to -1.1) missed | |
| Duloxetine (Cymbalta) | Approved | Small molecule | Serotonin/norepinephrine transporter, Serotonin and norepinephrine transporters (SERT/NET) | not yet graded | No reviewed efficacy summary in this indication | |
| Pregabalin | Approved | Small molecule | α2δ subunit of voltage-gated calcium channels | not yet graded | No reviewed efficacy summary in this indication | |
| Viloxazine (Qelbree) | Approved(overall) | Small molecule | norepinephrine transporter | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Reboxetine | Phase 3(overall) | Small molecule | norepinephrine transporter | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| ONO-1110 | Phase 2 | Small molecule | Endocannabinoid synthesis | not yet graded | No reviewed efficacy summary in this indication | |
| Ampreloxetine (TD-9855) | Discontinued | Small molecule | norepinephrine transporter | Partial signal(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Esreboxetine to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (2)
March 2028 (1)
Company guidance: topline data expected 3Q 2027 (Axsome Therapeutics, 2 Nov 2026). “AXS-14 for the management of fibromyalgia Key eligibility criteria ≥18 years of age with diagnosis of fibromyalgia Primary endpoint Time from randomization to loss of therapeutic response FORWARD Phase 3 trial Placebo AXS-14 (8 mg) Open-label period (12 weeks) Double-blind phase (up to 12 weeks) Baseline 1:1 R AXS-14 (8 mg) 1:1 randomization (Patients achieving treatment response) 45 Enrollment completion anticipated 3Q 2027” Source ↗